Controlled-release of epidermal growth factor from cationized gelatin hydrogel enhances corneal epithelial wound healing

Journal of Controlled Release

Volumn 118, Issue 2, 2007, Pages 169-176

  Hori, Kuniko ^a   Sotozono, Chie ^a   Hamuro, Junji ^a   Yamasaki, Kenta ^a   Kimura, Yu ^b   Ozeki, Makoto ^b   Tabata, Yasuhiko ^b   Kinoshita, Shigeru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Cationized gelatin hydrogel; Controlled release; Corneal wound healing; Epidermal growth factor; Hydrogel degradation

Indexed keywords

COMPUTER SOFTWARE; CONTACT LENSES; CONTROLLED DRUG DELIVERY; GROWTH KINETICS; IMAGE ANALYSIS; MEDICAL PROBLEMS; RADIOACTIVITY;

CATIONIZED GELATIN HYDROGEL (CGH); CONTROLLED RELEASE; CORNEAL WOUND HEALING; EPIDERMAL GROWTH FACTOR (EGF); HYDROGEL DEGRADATION;

HYDROGELS;

GELATIN; IODINE 125; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORNEA INJURY; DRUG DELIVERY SYSTEM; DRUG DESIGN; FEMALE; HYDROGEL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; WOUND HEALING;

ANIMALS; CATIONS; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CONJUNCTIVA; CORNEAL DISEASES; CROSS-LINKING REAGENTS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG COMPOUNDING; EPIDERMAL GROWTH FACTOR; EPITHELIUM, CORNEAL; FEMALE; GELATIN; GLUTARAL; HUMANS; HYDROGELS; MICE; RABBITS; RECOMBINANT PROTEINS; SOLUBILITY; TIME FACTORS; WOUND HEALING;

EID: 33847307132     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.12.011     Document Type: Article

References (54)

1. Imanishi J., Kamiyama K., Iguchi I., Kita M., Sotozono C., and Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog. Retin. Eye Res. 19 1 (2000) 113-129
2. Klenkler B., and Sheardown H. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp. Eye Res. 79 5 (2004) 677-688
3. Kitazawa T., Kinoshita S., Fujita K., Araki K., Watanabe H., Ohashi Y., and Manabe R. The mechanism of accelerated corneal epithelial healing by human epidermal growth factor. Invest. Ophthalmol. Vis. Sci. 31 9 (1990) 1773-1778
4. Kinoshita S. Clinical application of epidermal growth factor in ocular surface disorders. J. Dermatol. 19 11 (1992) 680-683
5. Daniele S., Frati L., Fiore C., and Santoni G. The effect of the epidermal growth factor (EGF) on the corneal epithelium in humans. Albrecht von Graefes Arch. Klin. Exp. Ophthalmol. 210 3 (1979) 159-165
6. Pastor J.C., and Calonge M. Epidermal growth factor and corneal wound healing. A multicenter study. Cornea 11 4 (1992) 311-314
7. Scardovi C., De Felice G.P., and Gazzaniga A. Epidermal growth factor in the topical treatment of traumatic corneal ulcers. Ophthalmologica 206 3 (1993) 119-124
8. Sotozono C., Inatomi T., Nakamura M., and Kinoshita S. Keratinocyte growth factor accelerates corneal epithelial wound healing in vivo. Invest. Ophthalmol. Vis. Sci. 36 8 (1995) 1524-1529
9. Fredj-Reygrobellet D., Plouet J., Delayre T., Baudouin C., Bourret F., and Lapalus P. Effects of aFGF and bFGF on wound healing in rabbit corneas. Curr. Eye Res. 6 10 (1987) 1205-1209
10. Rieck P., Assouline M., Savoldelli M., Hartmann C., Jacob C., Pouliquen Y., and Courtois Y. Recombinant human basic fibroblast growth factor (Rh-bFGF) in three different wound models in rabbits: corneal wound healing effect and pharmacology. Exp. Eye Res. 54 6 (1992) 987-998
11. Lambiase A., Rama P., Bonini S., Caprioglio G., and Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N. Engl. J. Med. 338 17 (1998) 1174-1180
12. Manning M.C., Patel K., and Borchardt R.T. Stability of protein pharmaceuticals. Pharm. Res. 6 11 (1989) 903-918
13. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185 2 (1999) 129-188
14. Frokjaer S., and Otzen D.E. Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4 4 (2005) 298-306
15. Bourlais C.L., Acar L., Zia H., Sado P.A., Needham T., and Leverge R. Ophthalmic drug delivery systems-recent advances. Prog. Retin. Eye Res. 17 1 (1998) 33-58
16. Shell J.W. Pharmacokinetics of topically applied ophthalmic drugs. Surv. Ophthalmol. 26 4 (1982) 207-218
17. MacKeen D.L. Aqueous formulations and ointments. Int. Ophthalmol. Clin. 20 3 (1980) 79-92
18. Hardberger R., Hanna C., and Boyd C.M. Effects of drug vehicles on ocular contact time. Arch. Ophthalmol. 93 1 (1975) 42-45
19. Hardberger R.E., Hanna C., and Goodart R. Effects of drug vehicles on ocular uptake of tetracycline. Am. J. Ophthalmol. 80 1 (1975) 133-138
20. Hull D.S., Edelhauser H.F., and Hyndiuk R.A. Ocular penetration of prednisolone and the hydrophilic contact lens. Arch. Ophthalmol. 92 5 (1974) 413-416
21. Hillman J.S., Marsters J.B., and Broad A. Pilocarpine delivery by hydrophilic lens in the management of acute glaucoma. Trans. Ophthalmol. Soc. U. K. 95 1 (1975) 79-84
22. Podos S.M., Becker B., Asseff C., and Hartstein J. Pilocarpine therapy with soft contact lenses. Am. J. Ophthalmol. 73 3 (1972) 336-341
23. Busin M., and Spitznas M. Sustained gentamicin release by presoaked medicated bandage contact lenses. Ophthalmology 95 6 (1988) 796-798
24. Friedberg M.L., Pleyer U., and Mondino B.J. Device drug delivery to the eye. Collagen shields, iontophoresis, and pumps. Ophthalmology 98 5 (1991) 725-732
25. Poland D.E., and Kaufman H.E. Clinical uses of collagen shields. J. Cataract Refract. Surg. 14 5 (1988) 489-491
26. Aquavella J.V., Ruffini J.J., and LoCascio J.A. Use of collagen shields as a surgical adjunct. J. Cataract Refract. Surg. 14 5 (1988) 492-495
27. Ikada Y., and Tabata Y. Protein release from gelatin matrices. Adv. Drug Deliv. Rev. 31 3 (1998) 287-301
28. Tabata Y., Nagano A., and Ikada Y. Biodegradation of hydrogel carrier incorporating fibroblast growth factor. Tissue Eng. 5 2 (1999) 127-138
29. Tabata Y., and Ikada Y. Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials 20 22 (1999) 2169-2175
30. Iwakura A., Tabata Y., Koyama T., Doi K., Nishimura K., Kataoka K., Fujita M., and Komeda M. Gelatin sheet incorporating basic fibroblast growth factor enhances sternal healing after harvesting bilateral internal thoracic arteries. J. Thorac. Cardiovasc. Surg. 126 4 (2003) 1113-1120
31. Sakakibara Y., Nishimura K., Tambara K., Yamamoto M., Lu F., Tabata Y., and Komeda M. Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation. J. Thorac. Cardiovasc. Surg. 124 1 (2002) 50-56
32. Tabata Y., Yamada K., Hong L., Miyamoto S., Hashimoto N., and Ikada Y. Skull bone regeneration in primates in response to basic fibroblast growth factor. J. Neurosurg. 91 5 (1999) 851-856
33. Nakano T., Kaibara K., Tabata Y., Nagata N., Enomoto S., Marukawa E., and Umakoshi Y. Unique alignment and texture of biological apatite crystallites in typical calcified tissues analyzed by microbeam X-ray diffractometer system. Bone 31 4 (2002) 479-487
34. Kimura Y., Ozeki M., Inamoto T., and Tabata Y. Adipose tissue engineering based on human preadipocytes combined with gelatin microspheres containing basic fibroblast growth factor. Biomaterials 24 14 (2003) 2513-2521
35. Tabata Y., Nagano A., Muniruzzaman M., and Ikada Y. In vitro sorption and desorption of basic fibroblast growth factor from biodegradable hydrogels. Biomaterials 19 19 (1998) 1781-1789
36. Fukunaka Y., Iwanaga K., Morimoto K., Kakemi M., and Tabata Y. Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation. J. Control. Release 80 1-3 (2002) 333-343
37. Kushibiki T., Tomoshige R., Fukunaka Y., Kakemi M., and Tabata Y. In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with different cationization extents. J. Control. Release 90 2 (2003) 207-216
38. Kushibiki T., Tomoshige R., Iwanaga K., Kakemi M., and Tabata Y. Controlled release of plasmid DNA from hydrogels prepared from gelatin cationized by different amine compounds. J. Control. Release 112 2 (2006) 249-256
39. Snyder S.L., and Sobocinski P.Z. An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. Anal. Biochem. 64 1 (1975) 284-288
40. C.o.M.f.T.P. Gelatin, PAGI (Photographic and Gelatin Industries) METHOD, 2002.
41. Greenwood F.C., Hunter W.M., and Glover J.S. The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem. J. 89 (1963) 114-123
42. Bolton A.E., and Hunter W.M. The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem. J. 133 3 (1973) 529-539
43. Ohashi Y., Motokura M., Kinoshita Y., Mano T., Watanabe H., Kinoshita S., Manabe R., Oshiden K., and Yanaihara C. Presence of epidermal growth factor in human tears. Invest. Ophthalmol. Vis. Sci. 30 8 (1989) 1879-1882
44. van Setten G.B., Tervo T., Viinikka L., Perheentupa J., and Tarkkanen A. Epidermal growth factor in human tear fluid: a minireview. Int. Ophthalmol. 15 6 (1991) 359-362
45. Mathers W.D., Sherman M., Fryczkowski A., and Jester J.V. Dose-dependent effects of epidermal growth factor on corneal wound healing. Invest. Ophthalmol. Vis. Sci. 30 11 (1989) 2403-2406
46. Sheardown H., Wedge C., Chou L., Apel R., Rootman D.S., and Cheng Y.L. Continuous epidermal growth factor delivery in corneal epithelial wound healing. Invest. Ophthalmol. Vis. Sci. 34 13 (1993) 3593-3600
47. Sheardown H., Clark H., Wedge C., Apel R., Rootman D., and Cheng Y.L. A semi-solid drug delivery system for epidermal growth factor in corneal epithelial wound healing. Curr. Eye Res. 16 3 (1997) 183-190
48. Jimmy O.D., and Bartlett D. Clinical Ocular Pharmacology (1984), Butterworth Publishers
49. Lee J. Formulation development of epidermal growth factor. Pharmazie 57 12 (2002) 787-790
50. Zhang Y., Liou G.I., Gulati A.K., and Akhtar R.A. Expression of phosphatidylinositol 3-kinase during EGF-stimulated wound repair in rabbit corneal epithelium. Invest. Ophthalmol. Vis. Sci. 40 12 (1999) 2819-2826
51. Gonul B., Erdogan D., Ozogul C., Koz M., Babul A., and Celebi N. Effect of EGF dosage forms on alkali burned corneal wound healing of mice. Burns 21 1 (1995) 7-10
52. Magun B.E., Planck S.R., Matrisian L.M., and Finch J.S. Binding, internalization and intracellular processing of 125I-epidermal growth factor purified by isoelectric focusing. Biochem. Biophys. Res. Commun. 108 1 (1982) 299-306
53. Kim E.Y., Gao Z.G., Park J.S., Li H., and Han K. rhEGF/HP-beta-CD complex in poloxamer gel for ophthalmic delivery. Int. J. Pharm. 233 1-2 (2002) 159-167
54. Watanabe K., Nakagawa S., and Nishida T. Stimulatory effects of fibronectin and EGF on migration of corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 28 2 (1987) 205-211